rs730882028
Variant summary
Our verdict is Pathogenic. Variant got 16 ACMG points: 16P and 0B. PM1PM2PP3_StrongPP5_Very_Strong
The NM_000546.6(TP53):c.1000G>T(p.Gly334Trp) variant causes a missense change. The variant was absent in control chromosomes in GnomAD project. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★).
Frequency
Consequence
NM_000546.6 missense
Scores
Clinical Significance
Conservation
Genome browser will be placed here
ACMG classification
Verdict is Pathogenic. Variant got 16 ACMG points.
Transcripts
RefSeq
Ensembl
Frequencies
GnomAD3 genomes Cov.: 32
GnomAD4 exome Cov.: 30
GnomAD4 genome Cov.: 32
ClinVar
Submissions by phenotype
Hereditary cancer-predisposing syndrome Pathogenic:3
​The p.G334W variant (also known as c.1000G>T) is located in coding exon 9 of the TP53 gene. This alteration results from a G to T substitution at nucleotide position 1000. The glycine at codon 334 is replaced by tryptophan, an amino acid with highly dissimilar properties. This variant was detected in one Korean individual's non-small cell lung cancer tumor sample along with another TP53 mutation (Lee et al. J Korean Med Sci. 2010. 25:698-705). The p.G334W alteration is located in the tetramerization domain of the protein which is critical in tumor suppressor activity. Another alteration at codon 334 (p.G334V) showed lower DNA binding activity and transactivation ability in thermal stability studies (Kamada et al. J Biological Chem. 2011 Jan; 286(1):252-258). This variant was not reported in population-based cohorts in the following databases: Database of Single Nucleotide Polymorphisms (dbSNP), NHLBI Exome Sequencing Project (ESP) and 1000 Genomes Project. Based on protein sequence alignment, this amino acid position is highly conserved in available vertebrate species. In addition, this alteration is predicted to be deleterious by in silico analysis. Based on the majority of available evidence to date, this variant is likely to be pathogenic. -
- -
This missense variant replaces glycine with tryptophan at codon 334 in the tetramerization domain of the TP53 protein and is located 7 nucleotides from the intron 9 splice acceptor site. This variant alters the conserved glycine residue that connects a short beta-strand (Glu326-Arg333) and an alpha-helix (Arg335-Gly356) of each subunit of the tetramer by facilitating a sharp turn (PMID: 20516128, 26572807). Computational prediction suggests that this variant may have deleterious impact on protein structure and function (internally defined REVEL score threshold >= 0.7, PMID: 27666373). Functional studies performed in yeast assays and ex vivo cultured cells have shown that this variant has largely neutral effect on the tetramer formation and transactivation function of the TP53 protein (PMID: 12826609, 16007150, 19454241) and does not exhibit dominant negative effect or loss of TP53 function in a human cell growth suppression assay (PMID: 30224644). This variant has been observed to segregate with breast cancer, glioblastoma brain cancer, esophageal and rectal cancer in a family affected with Li-Fraumeni syndrome (Color internal data). This variant has not been identified in the general population by the Genome Aggregation Database (gnomAD). A different variant occurring at the same codon, p.Gly334Arg, has been observed in multiple families affected with Li-Fraumeni syndrome meeting Chompret criteria (PMID: 23580068, 25503501, 25584008, 32675277; ClinVar variation ID: 182969) with reported incomplete penetrance (PMID: 25584008, 32675277), indicating that glycine at this position is important for TP53 function. Based on the available evidence, this variant is classified as Likely Pathogenic. -
Li-Fraumeni syndrome 1 Pathogenic:1
- -
Computational scores
Source:
Splicing
Find out detailed SpliceAI scores and Pangolin per-transcript scores at